Ro Real Customer Outcomes: An Evidence-Based Review of Results, Costs, and Alternatives

Is Ro a Legitimate Telehealth Platform?

Ro operates as a licensed telehealth company with prescribers credentialed in all 50 US states. The platform holds LegitScript certification, which requires independent verification of pharmacy licensing, prescriber credentials, and regulatory compliance. Ro's affiliated pharmacies are licensed by their respective state boards of pharmacy and registered with the FDA.

That does not make every Ro program equally effective. Legitimacy and clinical efficacy are separate questions. A platform can be fully licensed while offering treatments with variable evidence behind them. The strongest outcome data behind Ro's offerings come from its GLP-1 weight-loss program, where the active molecules (semaglutide, tirzepatide) have been tested in large, multi-center randomized controlled trials. Its ED and hair-loss programs rely on well-established generic medications (sildenafil, finasteride) with decades of trial data. The mental health program, which prescribes SSRIs and other psychiatric medications via asynchronous visits, raises more nuanced questions about whether text-based evaluation provides adequate diagnostic assessment for psychiatric conditions.

Ro earned an A+ rating from the Better Business Bureau, though BBB scores reflect complaint-resolution practices more than clinical quality. The platform has fulfilled over 20 million telehealth visits since launch, according to company disclosures.

GLP-1 Weight Loss Outcomes: What the Trials Actually Show

Ro's GLP-1 program prescribes semaglutide (branded as Wegovy, or compounded versions) and, in some cases, tirzepatide. The clinical outcomes patients can reasonably expect from these molecules are well-documented in Phase III trials, independent of the prescribing platform.

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [1]. That trial enrolled adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and included lifestyle intervention in both arms. The SURMOUNT-1 trial (N=2,539) tested tirzepatide at three doses and found that the highest dose (15 mg) produced 22.5% mean weight loss at 72 weeks versus 2.4% for placebo [2]. Over one-third of participants on the 15 mg dose lost ≥25% of body weight.

These numbers represent averages. Individual response varies considerably. In STEP-1, approximately 86% of semaglutide-treated participants achieved ≥5% weight loss, but only about 32% reached ≥20% [1]. The distribution matters more than the mean.

A key consideration for Ro's program: some patients receive compounded semaglutide rather than brand-name Wegovy. The FDA has raised concerns about compounded GLP-1 products, noting that compounded versions are not FDA-approved, may use salt forms (semaglutide sodium) not proven bioequivalent to the branded product, and are not subject to the same manufacturing standards. Patients should ask which formulation they are receiving and whether it is the branded product or a compounded alternative.

ED Treatment Outcomes Through Ro

Ro's erectile dysfunction program prescribes sildenafil (generic Viagra), tadalafil (generic Cialis), and branded versions of both. These are PDE5 inhibitors with extensive clinical validation spanning more than 25 years.

A meta-analysis of 130 randomized trials found that PDE5 inhibitors improved erectile function scores by a mean of 5.0 to 7.4 points on the IIEF-EF domain (scale: 1 to 30), with efficacy rates between 65% and 82% depending on the drug and dose [3]. Sildenafil 100 mg and tadalafil 20 mg showed comparable efficacy. Tadalafil offers a longer duration of action (up to 36 hours versus 4 to 6 hours for sildenafil), which is why some patients prefer it. Tadalafil 5 mg daily dosing is also available through Ro for patients who want continuous coverage rather than on-demand use.

The telehealth delivery model raises one clinical question. Standard of care for new-onset ED includes evaluation for cardiovascular risk factors, since ED can be an early marker of endothelial dysfunction and coronary artery disease. The American Urological Association guidelines recommend a focused history, physical examination, and basic lab work (fasting glucose, lipid panel, testosterone) for initial evaluation [4]. Asynchronous telehealth platforms, including Ro, generally rely on patient-reported questionnaires rather than physical exams or labs. This is a known trade-off in the telemedicine model: access improves, but in-person assessment is deferred.

Ro's pricing for ED medications has shifted over time. Generic sildenafil through Ro typically runs $2 to $6 per dose, which is competitive with GoodRx pricing at retail pharmacies but higher than some competitors like Cost Plus Drugs.

Hair Loss Treatment: Finasteride and Minoxidil Results

Ro prescribes oral finasteride (1 mg daily), topical minoxidil (5%), and combination products for androgenetic alopecia. These are the two medications with the strongest evidence for male pattern hair loss.

A 5-year study of finasteride 1 mg in 1,553 men aged 18 to 41 showed that 48% of treated men had visible hair regrowth at 1 year, with 90% demonstrating either maintained or increased hair counts at 5 years versus continued loss in the placebo group [5]. The Endocrine Society's 2019 clinical practice guideline acknowledges finasteride as a first-line pharmacologic option for androgenetic alopecia in men [6].

Sexual side effects remain the primary concern. In the original registration trials, 3.8% of finasteride-treated men reported decreased libido versus 2.1% on placebo. The concept of "post-finasteride syndrome" (persistent sexual and neurological symptoms after discontinuation) has been debated. A systematic review in JAMA Dermatology found that while sexual adverse effects are more common with finasteride, the evidence for persistent post-discontinuation symptoms is limited by small sample sizes and methodological concerns [7]. Ro's intake questionnaire asks about sexual function history, but the depth of informed-consent counseling around this issue varies by provider.

Minoxidil 5% foam or solution, available OTC, adds a complementary mechanism. Combination therapy (finasteride plus minoxidil) outperforms either alone. Results take 3 to 6 months to become visible and require ongoing use.

Mental Health Prescribing: Where Ro's Model Gets Complicated

Ro offers treatment for anxiety and depression, prescribing SSRIs (sertraline, escitalopram), bupropion, and buspirone through asynchronous consults. This is the area where the telehealth model faces the most scrutiny.

The American Psychiatric Association's practice guidelines recommend that initial psychiatric evaluation include a comprehensive history, mental status examination, risk assessment for suicidality, and consideration of comorbid substance use disorders [8]. Asynchronous text-based platforms compress this process into structured questionnaires. Whether that format captures sufficient clinical nuance for psychiatric prescribing is debated among clinicians.

Dr. John Torous, director of digital psychiatry at Beth Israel Deaconess Medical Center, has noted: "The question isn't whether telehealth can deliver psychiatric medications. It's whether the evaluation preceding that prescription is thorough enough to get the diagnosis right in the first place."

For straightforward cases of mild-to-moderate depression or generalized anxiety in patients without complex psychiatric histories, async prescribing of first-line agents like sertraline or escitalopram is arguably reasonable. The STAR*D trial (N=4,041) found that only about 33% of patients achieved remission on their first antidepressant trial [9]. That means two-thirds of patients needed medication adjustments, switches, or augmentation. Effective psychiatric care is iterative. How well Ro's asynchronous follow-up model supports that iteration compared to synchronous visits is an open question.

Ro Pricing Breakdown: What You Actually Pay

Ro uses a cash-pay model for most programs. Insurance is accepted in limited cases, primarily for certain branded GLP-1 medications. Here is a pricing summary based on publicly available information as of early 2026.

The GLP-1 program charges $99 per month for the subscription, plus medication costs that range from approximately $299 to $499 per month for compounded semaglutide. Brand-name Wegovy, if covered by insurance and prescribed through Ro, follows the patient's copay structure. Without insurance, Wegovy lists at approximately $1,349 per month.

ED medications through Ro cost roughly $2 to $6 per dose for generic sildenafil, $9 to $11 per dose for generic tadalafil, and higher for branded options. Monthly subscription plans that bundle consultations with medication supply typically run $20 to $90 per month depending on dose and quantity.

Hair loss treatment plans cost $15 to $45 per month for generic finasteride, with combination kits (finasteride plus minoxidil plus biotin shampoo) running $30 to $80 per month.

Mental health consultations are free, with medication costs depending on the specific drug and whether the patient uses Ro's pharmacy or a retail pharmacy with insurance. Generic SSRIs are among the cheapest prescription medications available ($4 to $15 per month at most pharmacies).

Ro vs. Alternatives: How It Compares

Several telehealth platforms compete directly with Ro across its core verticals. The comparison depends on which service you need.

For GLP-1 weight loss, Ro competes with Hims & Hers, Calibrate, Found, and Sequence. Calibrate differentiates by requiring metabolic lab work and offering a structured year-long program. Hims & Hers has aggressively priced compounded semaglutide but faces the same FDA scrutiny around compounded products [10]. Direct comparison of clinical outcomes between platforms is not possible because none publish head-to-head data or standardized outcome metrics.

For ED, Ro competes with Hims, BlueChew, and traditional urology practices. BlueChew offers chewable sildenafil and tadalafil at comparable prices. The molecules are identical across all platforms [3]. Price and convenience drive the choice.

For hair loss, Ro and Hims are near-identical in their offerings. Both prescribe finasteride and minoxidil. Both offer combination kits. Pricing is competitive between them. Keeps is another competitor with a similar product lineup.

The Endocrine Society's Dr. Maria Fleseriu has stated: "When patients have access to the same FDA-approved medications regardless of the platform, the distinguishing factors become clinical oversight quality, follow-up frequency, and how well the platform handles treatment failures or adverse effects."

Limitations of Platform-Based Outcome Claims

No major telehealth platform, including Ro, publishes peer-reviewed outcome data specific to its patient population. The weight-loss percentages, hair-regrowth rates, and ED improvement scores that platforms cite in marketing materials are drawn from clinical trials conducted in controlled settings with specific inclusion criteria, scheduled follow-ups, and dietary interventions. These trials often exclude patients with complex comorbidities, polypharmacy, or poor adherence.

A real-world evidence study published in JAMA Network Open found that GLP-1 receptor agonist persistence at 12 months was approximately 56% in a commercially insured population [11]. That is, nearly half of patients discontinued within the first year. Trial-based efficacy numbers assume continuous use. Real-world effectiveness, which accounts for discontinuation, cost barriers, and side-effect intolerance, is consistently lower.

Patients evaluating Ro or any competing platform should anchor expectations to real-world data rather than optimal-scenario trial results. A 15% mean weight loss in STEP-1 becomes a population-level average of something considerably less when you factor in the 44% who stop the medication before reaching the 68-week mark.

Red Flags to Watch For With Any Telehealth Platform

Three patterns should prompt caution when using Ro or similar services. First, any platform that prescribes controlled substances (stimulants, benzodiazepines, opioids) without synchronous video or in-person evaluation raises regulatory and safety concerns. Ro does not prescribe Schedule II controlled substances, which is appropriate. Second, platforms that guarantee specific outcomes ("lose 20% of your body weight") are making promises that clinical evidence does not support for every individual. Third, compounded medications marketed as equivalent to FDA-approved branded products without clear disclosure of the differences warrant skepticism. The FDA's compounding guidance is explicit that compounded drugs are not FDA-approved and are not evaluated for safety, efficacy, or manufacturing quality in the same way [10].

Patients should verify that their prescriber holds an active, unrestricted license in their state, that the pharmacy is state-licensed and DEA-registered, and that informed consent covers off-label use when applicable. Ro meets these baseline requirements based on its LegitScript certification and state licensing disclosures.